FDA Accepts Resubmitted New Drug Application for APL-130277 Apomorphine Film, Sunovion Announces

FDA Accepts Resubmitted New Drug Application for APL-130277 Apomorphine Film, Sunovion Announces
The U.S. Food and Drug Administration has accepted Sunovion‘s resubmitted new drug application (NDA) for APL-130277, an oral apomorphine therapy for treating off episodes in Parkinson’s disease. The FDA had asked for additional information regarding APL-130277, following the first NDA in mid-2018. A response to this resubmission is expected by May 21. APL-130277 is an under-the-tongue (sublingual) apomorphine film that ... read more
Source: Parkinson’s News TodayPublished on 2020-01-06By Forest Ray